PositiveID Corp (OTCMKTS:PSID) has successfully completed the second phase trials of its Firefly DX prototype. The device is a real-time polymerase chain pathogen detection system and is capable of detecting up to four pathogens in multiple organisms, with a multiplex assay. The goal of the company was to provide the medical industry, with quick and accurate results when needed. Normally lab tests can take up to several days to produce these results, but with the firefly DX, health care providers will be able to see the changes in real-time. The expected time for the device to generate results is 20 minutes.
The second phase provided the company with consistent and correct results of each challenge that the device was put through. The company also announced that the firefly would be available for use in lab quality detection of pathogenic organisms, agriculture and biological agents used in weapons of mass destruction. The device would be available worldwide after completion. The prototype is planned to be put through further screening by using assays developed by the company and its partners. The company also plans to reduce the time it takes the PCR chip to process the results.
The CEO of PositiveID Corp (OTCMKTS:PSID), William J. Caragol, shared his views that his device is a move in the direction of fast and efficient lab tests. The device can identify multiple organisms in a single sample, which can then be used by healthcare officials to find the cause for the patient’s symptoms. On the financial side, the new device would help the company tap into the global PCR market, which is expected to rise to $27.4 billion this year. The company had filed for the patent of the firefly DX earlier in the month of March, which was the 17th pending patent from the company. There is a lot more in the pipeline for the company than meets the eye, and future success stories might be along the way.